Breaking tumor-induced immunosuppression with 5'-triphosphate siRNA silencing TGFβ and activating RIG-I

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Schnurr, Max ^a   Duewell, Peter ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Immunosuppression; Pancreatic cancer; RIG I; SiRNA; TGF

Indexed keywords

5' TRIPHOSPHATE RNA; CASPASE 9; INTERFERON; PROTEIN BCL 2; RETINOIC ACID INDUCIBLE PROTEIN I; RNA; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; CD8+ T LYMPHOCYTE; DOWN REGULATION; ENZYME ACTIVATION; GENE SILENCING; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PANCREAS CANCER; PROTEIN EXPRESSION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; UPREGULATION;

EID: 84886943543     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24170     Document Type: Article

References (10)

1. Massagué J. TGFbeta in Cancer. Cell 2008; 134:215-30; PMID:18662538; http://dx.doi.org/10.1016/j. cell.2008.07.001
2. Moutsopoulos NM, Wen J, Wahl SM. TGF-beta and tumors--an ill-fated alliance. Curr Opin Immunol 2008; 20:234-40; PMID:18486463; http://dx.doi. org/10.1016/j.coi.2008.04.003
3. Yang L, Pang Y, Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31:220-7; PMID:20538542; http://dx.doi. org/10.1016/j.it.2010.04.002
4. Dunn GP, Bruce AT, Sheehan KC, Shankaran V, Uppaluri R, Bui JD, et al. A critical function for type I interferons in cancer immunoediting. Nat Immunol 2005; 6:722-9; PMID:15951814; http://dx.doi.org/10.1038/ni1213
5. Hornung V, Ellegast J, Kim S, Brzózka K, Jung A, Kato H, et al. 5'-Triphosphate RNA is the ligand for RIG-I. Science 2006; 314:994-7; PMID:17038590; http://dx.doi.org/10.1126/science.1132505
6. Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, Wenzel M, et al. 5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I. Proc Natl Acad Sci U S A 2009; 106:12067-72; PMID:19574455; http://dx.doi.org/10.1073/pnas.0900971106
7. Besch R, Poeck H, Hohenauer T, Senft D, Häcker G, Berking C, et al. Proapoptotic signaling induced by RIG-I and MDA-5 results in type I interferonindependent apoptosis in human melanoma cells. J Clin Invest 2009; 119:2399-411; PMID:19620789
8. Poeck H, Besch R, Maihoefer C, Renn M, Tormo D, Morskaya SS, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008; 14:1256-63; PMID:18978796; http://dx.doi.org/10.1038/nm.1887
9. Yoneyama M, Fujita T. RNA recognition and signal transduction by RIG-I-like receptors. Immunol Rev 2009; 227:54-65; PMID:19120475; http://dx.doi. org/10.1111/j.1600-065X.2008.00727.x
10. Ellermeier J, Wei J, Duewell P, Hoves S, Stieg MR, Adunka T, et al. Therapeutic efficacy of bifunctional siRNA combining TGF-beta1 silencing with RIG-I activation in pancreatic cancer. Cancer Res 2013; In press; PMID:23338611; http://dx.doi. org/10.1158/0008-5472.CAN-11-3850